Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.
This story was automatically imported from our syndicated feed coverage. Full updates are being tracked closely as more details emerge from local correspondents and global news wires.
Our editorial team is continuously monitoring this topic to bring you the latest developments. Check back regularly for detailed follow-up articles, background analyses, and video broadcasts from the scene.
Reporting sponsored by News Portal Syndicated Coverage.